摘要The science of one's genetic background and its impact on disease susceptibility and drug response has come of age and 昀rmly established its proper place in the clinic. Its impact is felt more in the treatment of cancer than any other disease area several reasons: critical time, narrow therapeutic index and overlapping toxicity window. We realize that the true potential of pharmacogenetics will be realized when we have been able to integrate other variants like insertion-deletion, copy number variation, etc., in addition to single nucleotide polymorphism for their collective influence on drug response and toxicity. Technology has rapidly evolved and has become a昀ordable to be used in the clinic once it gets standardized and validated not only in one population but in several major world population -particularly those which are under-represented in human variant database.